Dimethyl Fumarate Capsule, Delayed Release
Product Images NDC 33342-349

Product Visual Gallery

This gallery contains 8 technical images submitted to the FDA as part of the official labeling for Dimethyl Fumarate (NDC 33342-349). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Macleods Pharmaceuticals Limited, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

368 (Dimethyl Fumarate 14 Blister Carton Pack)

This is a description for Dimethyl Fumarate Delayed-Release Capsules USP, 120 mg. The capsules are dispensed in an original package. The text seems to contain information related to the product's composition and packaging, including dosage and the presence of a delayed-release mechanism.*

FDA Label Image

322 (Dimethyl Fumarate 60s Bottle 120mg)

Each capsule of MAcLOD contains 120 mg of dimethyl fumarate, USP. It is a Delayed-Release Capsule to be taken orally. Instructions suggest storing between 15°C to 30°C (59°F to 86°F). This pharmaceutical product is manufactured by Macleods Pharma USA, Inc., and Macleods Pharmaceuticals Ltd. It is important to swallow the capsule whole and protect it from light. The dosage information is available in the insert.*

FDA Label Image

369 (Dimethyl Fumarate 60s Bottle 240mg)

This text provides information about a medication named Dimethyl Fumarate, containing 240 mg, to be taken twice a day. The capsules are delayed-release and should be swallowed whole. The medication should be stored at controlled room temperature and protected from light. The product is manufactured by Macleods Pharma USA, Inc., and the contact information is provided.*

FDA Label Image

Fig (Dimethyl Fumarate Fig 1)

This is a table showing the percentage of subjects with confirmed progression of disability over time on study weeks. The data compares the placebo group to the Dimethyl Fumarate 240 mg BID group. Confirmed progression of disability is defined as at least a 10-point increase on the EDSS from a baseline EDSS greater than or equal to 10 confirmed for 12 weeks, or at least a 15-point increase on the EDSS from a baseline EDSS of 0 confirmed for 12 weeks.*

FDA Label Image

012 (Dimethyl Fumarate Starter Pack 1)

FDA Label Image

316 (Dimethyl Fumarate Starter Pack 120 mg)

This is a description of Dimethyl Fumarate Delayed-Release Capsules USP. It includes information about packaging, storage temperature, and dosage form.*

FDA Label Image

366 (Dimethyl Fumarate Starter Pack 240 mg)

FDA Label Image

Str (Dimethyl Fumarate Str)

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.